First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Theravance Biopharma, Inc.

    TBPH · 2 developments mapped · last assessed 2026-09-10

    Market Ontology has mapped 2 macro, policy, and market developments to Theravance Biopharma, Inc. since 2026-08-21. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for TBPH yet, so no modelled value is shown. The TBPH valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run TBPH on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for TBPH. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVR

      Direct acquisition of the company at a premium to its pre-announcement trading price.

      · Moves implied acquisition premium, probability of deal close

    • Main threat

      Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. merger

      Direct impact on merger completion probability and potential legal costs.

      · Moves probability of merger completion, synergy realization timeline, legal expenses

    What changed, by assumption

    Implied acquisition premium
    • 2026-08-21Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVR
    Probability of merger completion
    • 2026-09-10Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. merger

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-10RevenueBullishHigh confidence in achieving the $100 million 2026 milestone payment from Royalty Pharma based on TRELEGY global net sales.0.90
    2026-06-29Valuation multipleBullishTarget re-rates to bid premium until close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-10Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. mergerBearish1-3m0.70
    2026-08-21Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVRBullishintraday0.90